LH — Labcorp Holdings Inc.

As of 2026-09-13 the sell-side is still constructive - 26 Buy vs. 0 Sell ratings, consensus price target $337.29 (recent average $340.14, high $380, low $300) - but the tape has cooled: shares fell ~4.7% in the week to 2026-09-13 and are -3.69% over the past month, the direct result of management delivering in-line rather than above-consensus multi-year targets at the Sept 10 Investor Day. That reaction is a valuation reset, not a thesis break: the stock is still +17.05% over three months and +18.1% over six, RSI(14) sat at 40.86 on 2026-09-13, and the fundamental news flow (Q2 beat, $8.71B backlog up 10% YoY, MLM Medical Labs acquisition) is positive. The message from the market is 'good business, already priced for it.'

Revenue growth has clearly decelerated but stabilized: YoY growth ran +9.5% in Q2 2025 and +8.6% in Q3 2025, then stepped down to +5.6% (Q4 2025), +5.8% (Q1 2026) and +5.8% (Q2 2026) - three straight quarters at ~5.7-5.8% on a sequentially rising base ($3.52B -> $3.52B -> $3.56B -> $3.54B -> $3.73B), with Q2 2026 revenue of $3,731.1M a company record. That is a genuine reset from high-single-digit to mid-single-digit growth, NOT a structural break. The offsetting trend is margin: operating margin was 6.5% in Q4 2024 and 7.7% in Q3 2024, then 9.8% (Q1 2025), 11.2% (Q2 2025), 11.1% (Q3 2025), 10.9% (Q4 2025), 11.0% (Q1 2026) and 12.1% (Q2 2026) - TTM operating margin 11.3%, gross margin 27.8%. Diluted EPS followed: $3.64 in Q2 2026 vs $2.84 a year earlier (+28%), TTM GAAP EPS $12.27. Be aware quarterly GAAP earnings are lumpy from charges - Q4 2025 net income was only $164.7M ($1.98 EPS) versus $2.52-$3.12 in the surrounding quarters - while Q2 2026 adjusted EPS of $4.99 beat the $4.78 consensus. Cash quality is good: the accruals ratio was -0.79% at 2026-06-30 (operating cash flow running ahead of net income), and while quarterly FCF is seasonal and lumpy (Q1 2025 -$107.5M, Q1 2024 -$163.6M, Q1 2026 +$70.5M), trailing-twelve-month FCF is ~$1.16B against $1.24-1.36B of full-year 2026 guidance. Net read: an earnings-quality inflection driven by margin, on slower but steady top-line growth.

Fair, leaning slightly full. As of 2026-09-13 at $311.54, LH traded at 25.6x trailing GAAP EPS of $12.27 (vs. a 5-year average P/E of 24.47x - a modest premium to its own history) and 1.78x sales vs. a 5-year average of 1.63x (~9% premium). The flattering number is the forward P/E: $311.54 / $18.351 = 17.0x. But note that the $18.351 next-FY estimate effectively IS the company's own FY2026 adjusted EPS guidance of $18.10-18.55, so that ~17x is on adjusted earnings that exclude roughly $5-6/share of amortization and charges; on likely FY2026 GAAP EPS of ~$13, the multiple is closer to 24x. PEG of 0.772 looks cheap only because it pairs a depressed trailing GAAP base with headline growth. EV/EBITDA is 14.95x and P/B 2.96x, both unremarkable for a 5-6% revenue grower with 7.4% ROIC. Offsetting support: an ~5% FCF yield (~$1.30B guided 2026 FCF on a $25.5B cap), a 0.86% dividend, and a 0.79x debt/equity with a 1.80x current ratio. Conclusion: you are paying a full-ish price for a defensive, mid-single-digit grower with a genuine margin story - reasonably valued, not a bargain.

The crux is that $311.54 already capitalizes most of the guided 8.5-11.5% adjusted EPS CAGR. Labcorp spent 2025-26 re-rating from a 52-week low of $244.52 to a high of $341.80 as operating margin went from ~6.5-7.7% to ~11-12%; the Sept 10 Investor Day simply did not add incremental upside, which is why a 4.4% one-day fall (-4.7% for the week) followed guidance that was merely in line. So the stock is pricing in roughly the mid-point of the multi-year plan, not a beat-and-raise cadence. Upside from here requires the $8.71B biopharma backlog (+10% YoY, book-to-bill 1.11x) to convert faster than guided, accretive M&A/buybacks funded by ~$1.3B of annual FCF, or faster digital pathology/AI-driven volume gains; downside comes if PAMA pricing pressure or a biopharma bookings slowdown hits revenue AND the multiple simultaneously. Practical rule: track GAAP EPS (TTM $12.27, and likely ~$13 for FY2026), not just the adjusted headline, and watch whether consensus 2027 EPS drifts above ~$20 - that, not the price chart, is what justifies a higher multiple. At ~17x forward adjusted / ~24x GAAP with ~10% EPS growth, risk and reward look roughly symmetrical right now.

Range-bound pullback inside an intact uptrend, as of 2026-09-13: RSI(14) was 40.86 - weak, but not oversold. Price sat 5.05% BELOW the 20-day moving average (roughly $328) yet 0.65% ABOVE the 50-day (roughly $310) and 12.61% ABOVE the 200-day (roughly $277). That is textbook trend structure (price > 50DMA > 200DMA) with short-term momentum cooling after the Investor Day drop. Entry-timing implication: the $305-$310 zone around the 50-day is the first real support and is a far more rational place to initiate than chasing the $341.80 high; a decisive close below the 50-day would argue for waiting for stabilization, while reclaiming the 20-day near $328 would confirm the pullback is over. Note these are 2026-09-13 levels - by the time you read this, RSI and the moving averages will have moved.

• Interest rates and cost of capital: elevated Treasury yields and geopolitical/oil-driven volatility periodically trigger risk-off rotations in healthcare; Labcorp's ~$1.3B of annual free cash flow and 0.851 beta make it a relative defensive, but its $5.86B of long-term debt against only $141.8M of cash at 2026-06-30 leaves it rate-sensitive on refinancing.
• Biopharma R&D funding cycle: biotech venture funding and large-pharma R&D budgets directly drive the Biopharma Laboratory Services segment; the $8.71B backlog (+10% YoY) and 1.11x book-to-bill suggest resilient demand despite broader biotech macro tightening.
• Reimbursement regulation: PAMA (Protecting Access to Medicare Act) remains the single biggest structural margin threat to the Diagnostics Laboratories segment, with legislative and rate-setting risk that could cap the pricing leverage behind the recent margin expansion.
• Healthcare sector rotation: the sector's defensive characteristics attract flows during macro stress but cede them during 'risk-on' phases, which is a meaningful part of the recent one-month weakness in an otherwise strong six-month tape.
• Clinical laboratory labor and input costs: wage inflation for phlebotomists and medical technologists, plus supply-chain costs for reagents and instruments, are the main operating headwinds to sustaining the 11-12% operating margin achieved over the last five quarters.

• Q3 2026 earnings on October 27, 2026 - the first real test of whether Diagnostics volume trends and the 12.1% Q2 operating margin hold, and whether the $8.71B biopharma backlog converts at the guided pace.
• Execution against the Investor Day 2029 targets: 5-8% organic revenue CAGR and 8.5-11.5% adjusted EPS CAGR - any upward revision or visible progress would re-rate the multiple from ~17x forward.
• Continued margin expansion and EPS delivery: adjusted EPS of $18.10-18.55 for 2026 versus ~$15.5 in 2025 implies a strong growth year; a third consecutive beat-and-raise quarter would restore the momentum lost at Investor Day.
• Capital deployment: ~$1.3B of guided 2026 FCF funds buybacks and bolt-on M&A (e.g., the MLM Medical Labs deal expanding central lab coverage across four continents) - accretive use of cash is a direct EPS lever.
• Adoption of digital pathology and AI-driven diagnostic tools, plus any favorable or unfavorable PAMA legislative outcome - both are margin-relevant swing factors.

• PAMA/Medicare reimbursement cuts compressing Diagnostics pricing - the clearest threat to the margin expansion that is currently carrying the earnings story while revenue growth is only ~5.8%.
• A biopharma R&D funding downturn would hit the Biopharma Laboratory Services segment's bookings and slow conversion of the $8.71B backlog, removing one of the few genuine growth accelerants.
• Earnings quality optics: the ~24x trailing GAAP P/E and the roughly $5-6/share gap between adjusted and GAAP EPS mean the headline '17x forward' multiple flatters the stock; with ROIC at only 7.4% and ROE at 10.2%, the business does not earn premium returns on capital.
• Leverage and liquidity: $5.86B of long-term debt versus $141.8M of cash at 2026-06-30 (the lowest cash balance in the 12-quarter dataset), with a current ratio of 1.80 - manageable, but less cushion than a year ago.
• Valuation/expectations risk after the run: shares are +17.05% over three months and +18.1% over six, and the Sept 10 Investor Day showed that merely in-line guidance is now punished; a revenue-growth disappointment on top of a full multiple could produce an outsized drawdown.

Labcorp is a solid, defensive, cash-generative operator with a real margin-improvement story (operating margin from 6.5% in Q4 2024 to 12.1% in Q2 2026, EPS +28% YoY) and a legitimately growing biopharma backlog - but at $311.54 as of 2026-09-13 it is fairly, not attractively, priced: ~17x forward adjusted EPS but ~24x GAAP, 1.78x sales vs. a 1.63x five-year average, and only 7.4% ROIC against ~10% guided EPS growth. My calculated fair value of ~$334 implies roughly 7% upside, which is not enough to justify buying into a stock that just stumbled on its own Investor Day. It is a reasonable hold and a sensible defensive position on a pullback toward the 50-day (~$310) or lower; it is not a compelling new-money buy at these levels.

Primary method: 18.0x applied to the FY2026 adjusted EPS guidance midpoint of $18.33 (the figure underlying FMP's $18.351 next-FY estimate), giving $330 - an 18x multiple is mid-range versus diagnostics peers and the stock's own historical forward range, and is justified by mid-single-digit revenue growth, ~10% EPS CAGR, and defensive cash generation. Cross-check: 14.0x FY2026E EBITDA of ~$2.35B (on $14.77B guided revenue at ~11.5% operating margin plus ~$0.65B D&A) less $5.72B net debt and divided by ~82.0M shares gives ~$331. I nudge the blend to $334 to credit the 10%-growing $8.71B biopharma backlog and the 8.5-11.5% multi-year EPS CAGR, while staying below the $337.29 sell-side consensus to reflect PAMA reimbursement risk and a 7.4% ROIC that does not support a premium multiple.